• Title/Summary/Keyword: somatropin

Search Result 4, Processing Time 0.026 seconds

Collaborative Study for the Establishment of KFDA Reference Standard for Somatropin (KS 98/674) (재조합 사람성장호르몬(소마트로핀)의 KFDA 표준품(KS 98/674) 설정 연구)

  • Shin, Won;Joung, Jee-Won;Jin, Jae-Ho;Bristow, Adrian F.;Sohn, Yeo-Won
    • YAKHAK HOEJI
    • /
    • v.45 no.2
    • /
    • pp.227-236
    • /
    • 2001
  • The complexity and variability of both the biologicals and the bioassays used to test them led to the use of the reference standard- a sample of the product of defined purity and potency, against which all preparations of that product must be calibrated. In order to prepare and establish KFDA reference standard for recombinant human growth hormone (somatropin), somatropin substance was filled in ampoules in National Institute for Biological Standards and Control (NIBSC). The candidate KFDA reference standard for somatropin (designated as 98/674) was evaluated to determine the suitability of serving as a KFDA reference standard for somatropin by the collaborative study, in which 10 laboratories participated. Physicochemical analysis and in vivo bioassay were performed by direct comparison with the international somatropin standard 88/624. 98/674 was identified as somatropin by SDS-PAGE, IEF, peptide mapping, and HPLC. Determination of somatropin content by SE-HPLC yielded a mean estimate of 2.01 mg somatropin per ampoule. Data from the study also yielded mean values of 0.39 $\pm$ 0.26% for high molecular weight impurities by SE-HPLC and mean values of 2.13 $\pm$ 1.29% for somatropin related proteins by RP-HPLC. Estimates of relative potency by weight gain bioassay in the hypophysectomised rats showed that relative potency of KS 98/674 was 1.07 aganist IS 88/624. Based on the results of the collaborative study, the candidate reference standard for somatropin is suitable to serve as a KFDA reference standard for somatropin.

  • PDF

Severe trismus due to bilateral coronoid process hyperplasia in growth hormone therapy patient: a case report

  • Lee, Sung-Tak;Chung, In-Kyo
    • Journal of the Korean Association of Oral and Maxillofacial Surgeons
    • /
    • v.38 no.4
    • /
    • pp.249-254
    • /
    • 2012
  • Bilateral coronoid process hyperplasia is a rare condition characterized by an enlarged mandibular coronoid process. The painless progressive reduction of a mouth opening is caused by coronoid process impingement on the posterior aspect of the zygomatic bone. Hyperplasia of the bilateral coronoid process leads to the restriction of a mandibular opening consequent to the impingement of the enlarged coronoid process on the temporal surface of the zygomatic bone or with the medial surface of the zygomatic arch. The process has been diagnosed as developmental hyperplasia. Otherwise, the development of the coronoid process may be associated with growth hormone. This paper describes a case of trismus caused by coronoid hyperplasia in an idiopathic short-stature patient who received growth hormone therapy by somatropin injections.